Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Higher Tyvaso Doses Better at Preventing PH-ILD Worsening

A high dose of Tyvaso (inhaled treprostinil) — at least nine breaths four times per day — is more effective at preventing clinical worsening than lower doses for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a new study indicates. “This analysis further reinforces that [Tyvaso]…

Pulnovo’s PADN Device Yields Improved Outcomes in PAH Trial

Treatment with Pulnovo Medical‘s pulmonary artery denervation (PADN) device improved exercise capacity, blood flow dynamics, and clinical outcomes for pulmonary arterial hypertension (PAH) patients in a clinical trial called PADN-CFDA, the company announced. “The PADN-CFDA results are very important because this was an adequately powered randomized controlled trial,…

PH Seen in More Than Half of Preterm Infants in Dutch Study

More than half of babies born preterm at a center in the Netherlands were found to have pulmonary hypertension (PH), a new study reports. Babies with PH were more likely to develop bronchopulmonary dysplasia (BPD), a breathing disorder where the lungs don’t develop correctly, and survival outcomes were poorer…

Adempas Improves Blood Flow Parameters in PH-HFpEF Trial

Treatment with Adempas (riociguat) improved blood flow measurements in people with pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF) in a clinical trial. Researchers say that further study is needed to determine the effect of Adempas on clinical outcomes like exercise capacity. The study, “…

Virtual Visits Likely Inadequate to Guide Pediatric PAH Care

Diagnostic testing plays an important role in guiding changes in treatment for children with pulmonary arterial hypertension (PAH), suggesting that virtual healthcare visits may not be an adequate substitute for in-person testing for many children with the disease. That’s according to the study, “Factors Determining Change in Treatment for…

PAH Patients Prefer Yutrepia Over Tyvaso in INSPIRE Study

Yutrepia, an inhaled formulation of treprostinil, was generally well tolerated and improved the quality of life for people with pulmonary arterial hypertension (PAH) in the Phase 3 INSPIRE clinical trial. The therapy was preferred by nearly all trial participants who switched to it from Tyvaso, an older inhaled…

Study Gauges Long-term Survival for PAH Patients on Opsumit

More than half of people with pulmonary arterial hypertension (PAH) who start daily treatment with oral Opsumit (macitentan) are expected to still be alive after nine years on the therapy, according to a new analysis of data from the SERAPHIN clinical trial and its open-label extension. “These analyses…